Patents by Inventor Malcolm J. Low

Malcolm J. Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Upstream control elements of the proopiomelanocortin gene and their use
    Patent number: 7745604
    Abstract: The nucleic acid sequence of the POMC enhancer is disclosed herein. Sequences from the human, rat, rabbit, hamster, mouse, and cow POMC enhancer are disclosed. Hybrid transgenes, comprising a POMC transcriptional control element operably linked to a nucleic acid sequence encoding a marker are also enclosed. In addition, transgenic mice carrying a hybrid transgene including a POMC control element operably linked to a marker are disclosed herein.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: June 29, 2010
    Assignee: Oregon Health & Science University
    Inventors: Malcolm J. Low, Marcelo Rubinstein, Flavio Silva Junqueira de Souza
  • Upstream control elements of the proopiomelanocortin gene and their use
    Patent number: 7125979
    Abstract: The nucleic acid sequence of the POMC enhancer is disclosed herein. Sequences from the human, rat, rabbit, hamster, mouse, and cow POMC enhancer are disclosed. Hybrid transgenes, comprising a POMC transcriptional control element operably linked to a nucleic acid sequence encoding a marker are also enclosed. In addition, transgenic mice carrying a hybrid transgene including a POMC control element operably linked to a marker are disclosed herein.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: October 24, 2006
    Assignee: Oregon Health & Science University
    Inventors: Malcolm J. Low, Marcelo Rubinstein, Flavio Silva Junqueira de Souza
  • Upstream control elements of the proopiomelanocortin gene and their use
    Publication number: 20040003422
    Abstract: The nucleic acid sequence of the POMC enhancer is disclosed herein. Sequences from the human, rat, rabbit, hamster, mouse, and cow POMC enhancer are disclosed. Hybrid transgenes, comprising a POMC transcriptional control element operably linked to a nucleic acid sequence encoding a marker are also enclosed. In addition, transgenic mice carrying a hybrid transgene including a POMC control element operably linked to a marker are disclosed herein.
    Type: Application
    Filed: January 3, 2003
    Publication date: January 1, 2004
    Applicant: Oregon Health & Science University
    Inventors: Malcolm J. Low, Marcelo Rubinstein, Flavio Silva Junqueira de Souza
  • Mammalian melanocortin receptors and uses
    Patent number: 6278038
    Abstract: This invention provides methods and reagents for developing naturally-occurring and synthetic agonists and antagonists specific for a mammalian melanocortin receptor, and the use of such agonists and antagonists for treatment and alleviation of dysfunction and disease. The invention specifically provides reagents and methods for developing naturally-occurring and synthetic agonists and antagonists specific for a mammalian melanocortin receptor termed MC5-R. The naturally-occurring and synthetic agonists and antagonists specific for the MC5-R receptor are provided by the invention for the treatment, control, amelioration and alleviation of diseases, and dysfunctional and abnormal states related to thermoregulatory disorders, as well as other diseases relating to exocrine gland disorders, including lacrimal gland dysfunction and sebaceous gland disorders including acne and other skin problems.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: August 21, 2001
    Assignee: Oregon Health and Science University
    Inventors: Roger D. Cone, Wenbiao Chen, Malcolm J. Low